Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University...
-
Upload
reina-woodcock -
Category
Documents
-
view
221 -
download
4
Transcript of Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University...
![Page 1: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/1.jpg)
Pharmacological Treatment of Addiction
David A. Fiellin, M.D.
Professor of Medicine
Yale University School of Medicine
![Page 2: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/2.jpg)
Overview
• Epidemiology of opioid dependence
• Treatment of opioid dependence– Buprenoprhine– Office-based treatment
• Epidemiology of alcohol problems
• Treatment of alcohol problems– Naltrexone, acamprosate, disulfiram
![Page 3: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/3.jpg)
• Physical Dependence– Tolerance– Withdrawal
• Loss of control (addiction)– Larger amounts/longer period than intended– Inability to/persistent desire to cut down or control– Increased amount of time spent in activities necessary to
obtain opioids– Social, occupational and recreational activities given up or
reduced– Opioid use is continued despite adverse consequences
Opioid Dependence (DSM-IV, 3 or more within one year)
![Page 4: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/4.jpg)
Epidemiology• Prescription opioids
– National Survey on Drug Use and Health, 2006• > 12 million reported non-medical use of prescription opioids • Estimated 1.6 million met criteria for prescription opioid abuse or
dependence
• Heroin– National Household Survey on Drug Abuse, 2006
• > 500,000 reported past year heroin use• Approximately 323,000 individuals met criteria for heroin abuse or
dependence
• Combined, 2 million opioid dependent in U.S.– In 2005 only 331,000 individuals entered treatment for opioid
dependence
![Page 5: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/5.jpg)
Prescription of Opioids• Between 1994 & 2003, prescriptions for:
– Non-controlled drugs increased by 57%
– Controlled substances increased by 154%.
Trescot et al. Pain Physician, 2008; 11: S5-62.
![Page 6: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/6.jpg)
0.10.1
0.20.2
0.60.6
0.60.6
0.70.7
0.60.6
2.02.0
6.26.2
14.614.6
00 11 33 55 77 99 1111 1313 1515
LSDLSD
HeroinHeroin
InhalantsInhalants
MethMeth
EcstasyEcstasy
CrackCrack
CocaineCocaine
Prescription DrugsPrescription Drugs
MarijuanaMarijuana
(incl. crack)(incl. crack)
Past Month Users, Ages 12 and Older (in Millions)Past Month Users, Ages 12 and Older (in Millions)
Source: SAMHSA, 2002 National Survey on Drug Use and Health.
Source: SAMHSA, 2002 National Survey on Drug Use and Health.
Nonmedical Use of Prescription Drugs
Nonmedical Use of Prescription Drugs
![Page 7: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/7.jpg)
![Page 8: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/8.jpg)
0
1
2
3
4
5
6
7
8
'90
'91
'92
'93
'94
'95
'96
'97
'98
'99
'00
'01
'02
'03
'04
'05
'06
Cru
de
ra
te p
er
10
0,0
00
0
100
200
300
400
500
600
Sa
les
in m
g/p
ers
on
Deaths per 100,000
Opioid sales (mg perperson)
Annual sales of prescription opioids and unintentional overdose death
1990 - 2006
Source: Paulozzi, CDC, Congressional testimony, 2007
![Page 9: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/9.jpg)
Brain’s Reward pathways
![Page 10: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/10.jpg)
![Page 11: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/11.jpg)
Changes in Neurobiology
• Repeated exposure to short acting opioids leads to neuronal adaptations– Mesolimbic dopaminergic system
• adaptations in G protein-coupled receptors• up regulation of cyclic cAMP second messenger pathway
• changes in transcription and translation
• Adaptations– Mediate tolerance, withdrawal, craving, self-adminstration– Provide insight into the chronic and relapsing nature of
opioid dependence– Form basis of pharmacotherapies to stabilize neuronal
circuits
![Page 12: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/12.jpg)
Opioid Treatment
![Page 13: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/13.jpg)
Pharmacologic Treatment of Opioid Dependence
• Pharmacologic withdrawal - “detoxification”
• Opioid antagonist treatment
– Naltrexone
• Opioid agonist treatment
– Methadone
– Buprenorphine
![Page 14: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/14.jpg)
Poor results with detoxification Kakko, Lancet 2003
Treatment duration (days)
Rem
aini
ng in
tre
atm
ent
(nr
)
0
5
10
15
20
0 50 100 150 200 250 300 350
Detoxification
Maintenance
![Page 15: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/15.jpg)
Opioid Agonist Treatment
• Rationale
– Cross-tolerance
• prevent withdrawal
• relieve craving for opioids
– Narcotic blockade
• block or attenuate euphoric effect of exogenous opioids
![Page 16: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/16.jpg)
How effective is opioid agonist treatment?
![Page 17: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/17.jpg)
Buprenorphine, Methadone, LAAM: Treatment Retention
Per
cent
Ret
aine
d
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
20% Lo Meth
58% Bup
73% Hi Meth
53% LAAM
Study Week
![Page 18: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/18.jpg)
![Page 19: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/19.jpg)
![Page 20: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/20.jpg)
![Page 21: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/21.jpg)
HIV Seroconversion
• Metzger, 1993:– 2 cohorts of patients
• 103 out-of-treatment intravenous opiate users
• 152 subjects receiving methadone treatment
– HIV antibody conversion, 18-months• 22% of those out-of-treatment
• 3.5% of those receiving methadone treatment
![Page 22: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/22.jpg)
Treatment vs. Addiction
MarkedAbsentEuphoria
3-6 hours24-36 hoursDuration
Immediate30 minutesOnset
IV, INOral, sublingualRoute
HeroinMethadone or buprenorphine
![Page 23: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/23.jpg)
Buprenorphine
• Partial agonist at mu receptor
• Low abuse and diversion potential, especially when combined with naloxone
• Can be prescribed from the office by a physician
• Sub-lingual tablet
• Daily or thrice weekly dosing
![Page 24: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/24.jpg)
-10 -9 -8 -7 -6 -5 -40
10
20
30
40
50
60
70
80
90
100
Intrinsic Activity
Log Dose of Opioid
Full Agonist(Methadone, oxycodone)
Partial Agonist(Buprenorphine)
Antagonist (Naltrexone)
Intrinsic Activity: Full Agonist (Methadone), Partial Agonist (Buprenorphine), Antagonist (Naloxone)
![Page 25: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/25.jpg)
Bup 00 mg
Bup 02 mg
Bup 16 mg
Bup 32 mg0 -
4 -
MRI
BindingPotential(Bmax/Kd)
Effects of Buprenorphine Dose on µ-Opioid Receptor Availability in a Representative Subject
![Page 26: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/26.jpg)
Federal Efforts to Increase AccessFiellin and O’Connor, NEJM 2002
• Congress (2000)• Drug Addiction Treatment Act
• Allows qualifying physicians to use approved schedule III-V medications
• Qualifying physician either certified in Addiction Medicine/Psychiatry or complete 8 hour training
• FDA and DEA (2002)• Approves buprenorphine and
buprenorphine/naloxone for treatment of opioid dependence, schedule III
![Page 27: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/27.jpg)
How effective is office-based buprenorphine treatment?
![Page 28: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/28.jpg)
Self-Reported Frequency of Illicit Opioid Use in Opioid-Dependent Patients Receiving Buprenorphine-Naloxone in Primary Care
Fiellin D et al. N Engl J Med 2006;355:365-374
![Page 29: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/29.jpg)
Retention among Opioid-Dependent Patients Receiving Buprenorphine-Naloxone in Primary Care
Fiellin D et al. N Engl J Med 2006;355:365-374
![Page 30: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/30.jpg)
6 Weeks of Opioid Abstinence
0
10
20
30
40
50
60
Heroin only Heroin &Prescription
Prescriptiononly
Per
cen
t o
pio
id n
egat
ive
Moore, JGIM, 2007
![Page 31: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/31.jpg)
66 Physicians and 31 Treatment Programs listed in Minnesota
![Page 32: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/32.jpg)
Trained, Registered and Prescribing Physicians
U.S. January 2009
8295
![Page 33: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/33.jpg)
Alcohol Treatment
![Page 34: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/34.jpg)
Patterns of Alcohol Use: Epidemiology
GeneralPopulation†
General MedicalPractice‡
1. Abstainers 40% ----
2. Moderate Drinkers 35% ----
3. At Risk
4. Alcohol Abuse 20% 20-35%
5. Alcohol Dependence 5% 5-10%
† National Longitudinal Alcohol Epidemiology Study 1992, National Comorbidity Study, 1992‡ Wallace; BMJ 1988;297:663-8, Flemming JAMA 1997;277:1039-45
![Page 35: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/35.jpg)
Terminology For Alcohol Use Behaviors
Term Description Moderate Drinking
men: women: over 65:
< 2 drinks/day < 1 drink/day < 1 drink/day
At Risk Drinking men: women:
> 14 drinks/week > 4 drinks /occasion > 7 drinks/week > 3 drinks/occasion
![Page 36: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/36.jpg)
What is a drink?
• 14 grams of alcohol– 12 ounces of beer– 5 ounces of wine– 1.5 ounces of
distilled spirits
![Page 37: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/37.jpg)
Alcohol TreatmentPharmacotherapy
![Page 38: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/38.jpg)
Disulfiram
Ethanol Acetaldehyde AcetateADH ALDH
Build up of acetaldehyde causes:-Flushing-Headache-Nausea-Dizziness-Palpitations
![Page 39: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/39.jpg)
Disulfiram Efficacy
• In a large double-blinded study, disulfiram was no better than placebo in helping patients remain abstinent
• A subset of relapsed patients, who were older and more socially stable, drank less
frequently when given disulfiram
• Greater efficacy has been shown with supervised disulfiram administration
Fuller PK, et al. JAMA 1986;256:1449-55
![Page 40: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/40.jpg)
Prescribing Disulfiram
• Start at 250mg daily and titrate to 500mg daily• Contraindications:
– Recent alcohol use– Pregnancy– Cognitive impairment
• Side effects:– Hepatotoxicity– Neuropathy
![Page 41: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/41.jpg)
Naltrexone
1. Mechanism of Action: opioid receptor blockade
2. Effects: decreased craving and alcohol consumption
3. Dose: 50 mg/day
4. Side Effects: nausea (10%), headache
5. Contraindications: opioid dependence
severe liver disease
![Page 42: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/42.jpg)
Combined Analysis ofYale and U Penn Studies of Naltrexone
• 12 week, double-blind, placebo controlled
• Concurrent Psychotherapy:
– Once weekly individual therapy (Yale)
– Day Hospital (1 month), twice weekly
group (2 months) (U Penn)
• Abstinence rates:
Naltrexone: 54%
Placebo: 31%
-------------O’Malley et al., Psychiatric Annals 1995;25:681-88.
![Page 43: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/43.jpg)
Naltrexone: Efficacy• Meta-analysis of 14 studies*
– Relapse to heavy drinking• Naltrexone 428/1142 (37%), control 445/930 (48%)
– Odds ratio for relapse• 0.62 (95% CI 0.52,0.75)
• COMBINE Study† (Naltrexone X 16 w, n=302)– Increased abstinence over placebo (81% vs. 75%)– Reduced risk of a heavy drinking day (HR 0.72,
p<0.02)
*Carmen B, Addiction 2004; † Anton RF, JAMA, 2004
![Page 44: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/44.jpg)
Prescribing Naltrexone
• 25 to 50 mg daily taken after a meal for at least 3-4 months
• Depot form available doses studied 190-380 mg– 25% reduction in heavy drinking days
• Contraindications:– Opioid use– Pregnancy
• Side Effects:– Nausea
Garbutt JC, JAMA, 2005, Anton R, NEJM, 2008
![Page 45: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/45.jpg)
Anton, R. F. et al. JAMA 2006;295:2003-2017.
Project Combine: Design
![Page 46: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/46.jpg)
Copyright restrictions may apply.
Anton, R. F. et al. JAMA 2006;295:2003-2017.
Project Combine: Effect Size Estimates and Hazard Ratios for
Primary Outcomes
![Page 47: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/47.jpg)
Garbutt, J. C. et al. JAMA 2005;293:1617-1625.
Injectable Naltrexone:Mean Heavy Drinking Event Rate
![Page 48: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/48.jpg)
Acamprosate
• Alcohol is an agonist at the inhibitory GABA receptors and antagonist at excitatory glutamate receptors
• Acamprosate modulates alcohol effects:– GABA-analogue– Modulates action at NMDA receptor
![Page 49: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/49.jpg)
Acamprosate: Efficacy• Meta-analysis of 7 placebo controlled trials*
– Acamprosate (n=1195), placebo (n=1027)– Proportion of patients continually abstinent at one
year 23% for acamprosate group, 15% for placebo group
• COMBINE study† (Acamprosate arm, n=300)– No significant effect on drinking over placebo
*Carmen B, Addiction 2004; †Anton, RF, JAMA 2004
![Page 50: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/50.jpg)
Prescribing Acamprosate
• 666 mg po TID; start after a period of abstinence
• Contraindications– CrCl < 30 cc/min– Pregnancy
• Side effects– Diarrhea
![Page 51: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/51.jpg)
Topiramate
• Reduces corticomesolimbic dopamine release– Agonist at GABA– Antagonist at glutamate
• Not FDA approved
![Page 52: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/52.jpg)
Topiramate: Efficacy• N=371, double blind randomized placebo
controlled trial• Intention-to-treat analysis
Topiramate Placebo pReduction in number of heavy drinking days
44% 52% 0.002
Increase in abstinence days (baselinewk 14)
10% to 38% 9% to 29% 0.002
Johnson BA, JAMA 2007
![Page 53: Pharmacological Treatment of Addiction David A. Fiellin, M.D. Professor of Medicine Yale University School of Medicine.](https://reader035.fdocuments.in/reader035/viewer/2022062511/551a5eb2550346cb358b6088/html5/thumbnails/53.jpg)
Summary• Opioid and alcohol problems are common• Effective therapies for opioid dependence
and alcohol use disorders exist• Office-based treatment of addictive disorders
may help increase access to treatment and decrease stigma